

ASX ANNOUNCEMENT

13 September 2022

ANTERIS TECHNOLOGIES AT THE TRANSCATHETER CARDIOVASCULAR THERAPEUTICS CONFERENCE

Anteris Technologies Ltd (ASX: AVR) (Anteris) is pleased to announce that it will present detailed results of the 30-day outcomes for the combined cohort of 13 patients, from the DurAVR™ THV First-In-Human (FIH) trial at the world's premier meeting for interventional cardiovascular medicine. Also refer to the summarised findings included in ASX Announcements dated 24 January 2022 and 11 July 2022.

The 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference organised by the Cardiovascular Research Foundation is held annually in Boston Massachusetts and attracts approximately 11,000 of the world's best practitioners in the field of interventional cardiology and vascular medicine. This year's meeting will be held from 16-19 September 2022.

Anteris has secured three opportunities at the conference to address its target market over the four-day event:

- **DurAVR™- Design, Concept and FIH Results**
 - Presenter: Dr. Vinayak Bapat, Minneapolis Heart Institute, Abbott Northwestern Hospital
- **First-In-Human Results with the Novel Anteris DurAVR™ 3D Single Piece TAVR Device**
 - Presenter: Dr. Chris Meduri, Anteris Chief Medical Officer (CMO) and Karolinska University Hospital, Stockholm.
- **Anteris Tech's DurAVR™ THV: Novel Leaflet Design and its Impact on Physiology & Clinical Performance**
 - Session Chairs: Dr. Samir Kapadia—Chair of Cardiovascular Medicine, Cleveland Clinic and Dr. Anita Asgar- Director of the TAVR Research at the Institut Cardiologie de Montreal
 - Presenters: Dr Van Miegham- Erasmus University, Rotterdam, Netherlands, Dr. Paul Sorajja - Director, Center of Valve and Structural Heart Disease, Minneapolis Heart Institute, Dr. Joao Cavalcante Minneapolis Heart Institute, Dr. Chris Meduri - Anteris CMO and Karolinska University Hospital, Stockholm, Sweden

In conjunction with its clinical presentations at TCT the Company will host a conference call/Key Opinion Leader forum to discuss the presented FIH data on Monday Sept 19, 2022, at 8 am EST (10 pm AEST). Participating doctors will include TAVR experts that performed the first-in-human implantations, Drs. Chris Meduri and Vinayak Bapat as well as Susheel Kodali - Director of the Structural Heart & Valve Center at New York-Presbyterian/Columbia University Medical Center.

Investors are invited to participate in the forum which can be accessed by live webcast link <https://event.on24.com/wcc/r/3928771/05E4E4A527DE8E788445CC3EE4E99B61>
A link to the replay will be made available in the following days at <https://anteristech.com/investors>

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info.au@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



“DurAVR™ represents a transformational product, and we are excited to showcase its first clinical study at one of the most prestigious interventional cardiology congresses” commented Dr Chris Meduri, Anteris CMO, and practicing interventional cardiologist at the Karolinska University Hospital, Stockholm.

“We have previously demonstrated that all Anteris tissue (including the FDA-approved product CardioCel®) made from our patented ADAPT® technology, have zero-DNA, zero-glutaraldehyde and are hence ultra-durable in the long-term because it remains calcification-free in 10-year longitudinal follow-ups. The FIH data produced to date now demonstrates the immediate benefit of Anteris’ single-piece 3D TAVR (DurAVR™). With its novel leaflet design and thus a larger, coaptation area mimicking the native aortic valve, DurAVR™ provides immediate haemodynamic benefits to patients with Aortic Stenosis. By providing both immediate (acute) and long term (chronic) benefits, DurAVR™ is ideally suited for patients of all ages with severe aortic stenosis. With the mean age of patients now being 73 (down from 85 in the past several years) DurAVR™ is particularly well suited to this younger patient population who need more normal haemodynamics and the potential for a longer-lasting valve, with superior anti calcification treatment (ADAPT®)”, commented Wayne Paterson, CEO.

END

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is on developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris’ DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of today’s younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Deanne Curry

GRACosway

E: investors@anteristech.com

M: +61 414 388 997

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech

LinkedIn: <https://www.linkedin.com/company/anteristech>